Does the media refer more to LMAT or NPCE?

In the previous week, LeMaitre Vascular had 9 more articles in the media than NeuroPace. MarketBeat recorded 11 mentions for LeMaitre Vascular and 2 mentions for NeuroPace. NeuroPace's average media sentiment score of 1.17 beat LeMaitre Vascular's score of 1.17 indicating that NeuroPace is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LeMaitre Vascular 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive NeuroPace 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NPCE or INSP?

In the previous week, Inspire Medical Systems had 7 more articles in the media than NeuroPace. MarketBeat recorded 9 mentions for Inspire Medical Systems and 2 mentions for NeuroPace. Inspire Medical Systems' average media sentiment score of 1.69 beat NeuroPace's score of 1.17 indicating that Inspire Medical Systems is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroPace 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inspire Medical Systems 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor NPCE or KMTS?

In the previous week, Kestra Medical Technologies had 1 more articles in the media than NeuroPace. MarketBeat recorded 3 mentions for Kestra Medical Technologies and 2 mentions for NeuroPace. NeuroPace's average media sentiment score of 1.17 beat Kestra Medical Technologies' score of 0.62 indicating that NeuroPace is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroPace 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kestra Medical Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, CNMD or NPCE?

CONMED has higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CONMED $1.37B 1.09 $47.06M $1.85 26.98 NeuroPace $99.99M 4.95 -$21.47M -$0.57 N/A

Is CNMD or NPCE more profitable?

CONMED has a net margin of 4.12% compared to NeuroPace's net margin of -19.34%. CONMED's return on equity of 14.31% beat NeuroPace's return on equity. Company Net Margins Return on Equity Return on Assets CONMED 4.12% 14.31% 6.33% NeuroPace -19.34% -105.64% -16.51%

Does the media favor CNMD or NPCE?

In the previous week, CONMED had 3 more articles in the media than NeuroPace. MarketBeat recorded 5 mentions for CONMED and 2 mentions for NeuroPace. NeuroPace's average media sentiment score of 1.17 beat CONMED's score of 0.95 indicating that NeuroPace is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CONMED 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive NeuroPace 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, OMCL or NPCE?

Omnicell has higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Omnicell $1.18B 1.27 $2.05M $0.84 39.38 NeuroPace $99.99M 4.95 -$21.47M -$0.57 N/A

Is OMCL or NPCE more profitable?

Omnicell has a net margin of 3.13% compared to NeuroPace's net margin of -19.34%. Omnicell's return on equity of 5.66% beat NeuroPace's return on equity. Company Net Margins Return on Equity Return on Assets Omnicell 3.13% 5.66% 3.57% NeuroPace -19.34% -105.64% -16.51%

Does the media refer more to OMCL or NPCE?

In the previous week, Omnicell had 5 more articles in the media than NeuroPace. MarketBeat recorded 7 mentions for Omnicell and 2 mentions for NeuroPace. Omnicell's average media sentiment score of 1.45 beat NeuroPace's score of 1.17 indicating that Omnicell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omnicell 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NeuroPace 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

NeuroPace (NPCE) Competitors

$14.41 +0.28 (+1.98%)

As of 08/28/2026 04:00 PM Eastern

Compare

NPCE vs. LMAT, INSP, KMTS, CNMD, and OMCL

Should you buy NeuroPace stock or one of its competitors? NeuroPace's main competitors and comparable companies include LeMaitre Vascular (LMAT), Inspire Medical Systems (INSP), Kestra Medical Technologies (KMTS), CONMED (CNMD), and Omnicell (OMCL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does NeuroPace compare to LeMaitre Vascular?

LeMaitre Vascular (NASDAQ:LMAT) and NeuroPace (NASDAQ:NPCE) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

84.6% of LeMaitre Vascular shares are held by institutional investors. Comparatively, 78.8% of NeuroPace shares are held by institutional investors. 7.4% of LeMaitre Vascular shares are held by company insiders. Comparatively, 19.2% of NeuroPace shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

LeMaitre Vascular presently has a consensus target price of $110.60, suggesting a potential upside of 37.48%. NeuroPace has a consensus target price of $19.29, suggesting a potential upside of 33.84%. Given LeMaitre Vascular's higher possible upside, analysts clearly believe LeMaitre Vascular is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

LeMaitre Vascular has a net margin of 25.02% compared to NeuroPace's net margin of -19.34%. LeMaitre Vascular's return on equity of 15.63% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	25.02%	15.63%	10.06%
NeuroPace	-19.34%	-105.64%	-16.51%

LeMaitre Vascular has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market. Comparatively, NeuroPace has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market.

In the previous week, LeMaitre Vascular had 9 more articles in the media than NeuroPace. MarketBeat recorded 11 mentions for LeMaitre Vascular and 2 mentions for NeuroPace. NeuroPace's average media sentiment score of 1.17 beat LeMaitre Vascular's score of 1.17 indicating that NeuroPace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LeMaitre Vascular	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
NeuroPace	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LeMaitre Vascular has higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$249.60M	7.37	$57.73M	$2.85	28.23
NeuroPace	$99.99M	4.95	-$21.47M	-$0.57	N/A

Summary

LeMaitre Vascular beats NeuroPace on 11 of the 17 factors compared between the two stocks.

How does NeuroPace compare to Inspire Medical Systems?

NeuroPace (NASDAQ:NPCE) and Inspire Medical Systems (NYSE:INSP) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

78.8% of NeuroPace shares are held by institutional investors. Comparatively, 94.9% of Inspire Medical Systems shares are held by institutional investors. 19.2% of NeuroPace shares are held by insiders. Comparatively, 2.2% of Inspire Medical Systems shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

NeuroPace has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market. Comparatively, Inspire Medical Systems has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market.

Inspire Medical Systems has a net margin of 15.03% compared to NeuroPace's net margin of -19.34%. Inspire Medical Systems' return on equity of 8.64% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroPace	-19.34%	-105.64%	-16.51%
Inspire Medical Systems	15.03%	8.64%	7.45%

In the previous week, Inspire Medical Systems had 7 more articles in the media than NeuroPace. MarketBeat recorded 9 mentions for Inspire Medical Systems and 2 mentions for NeuroPace. Inspire Medical Systems' average media sentiment score of 1.69 beat NeuroPace's score of 1.17 indicating that Inspire Medical Systems is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroPace	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inspire Medical Systems	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

NeuroPace presently has a consensus price target of $19.29, suggesting a potential upside of 33.84%. Inspire Medical Systems has a consensus price target of $66.19, suggesting a potential upside of 7.64%. Given NeuroPace's stronger consensus rating and higher probable upside, research analysts plainly believe NeuroPace is more favorable than Inspire Medical Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Inspire Medical Systems	3 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.21

Inspire Medical Systems has higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than Inspire Medical Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$99.99M	4.95	-$21.47M	-$0.57	N/A
Inspire Medical Systems	$911.98M	1.95	$145.42M	$4.62	13.31

Summary

Inspire Medical Systems beats NeuroPace on 11 of the 17 factors compared between the two stocks.

How does NeuroPace compare to Kestra Medical Technologies?

NeuroPace (NASDAQ:NPCE) and Kestra Medical Technologies (NASDAQ:KMTS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

NeuroPace currently has a consensus target price of $19.29, suggesting a potential upside of 33.84%. Kestra Medical Technologies has a consensus target price of $28.14, suggesting a potential upside of 9.76%. Given NeuroPace's stronger consensus rating and higher probable upside, analysts plainly believe NeuroPace is more favorable than Kestra Medical Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Kestra Medical Technologies	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

NeuroPace has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market. Comparatively, Kestra Medical Technologies has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market.

In the previous week, Kestra Medical Technologies had 1 more articles in the media than NeuroPace. MarketBeat recorded 3 mentions for Kestra Medical Technologies and 2 mentions for NeuroPace. NeuroPace's average media sentiment score of 1.17 beat Kestra Medical Technologies' score of 0.62 indicating that NeuroPace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroPace	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kestra Medical Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NeuroPace has higher revenue and earnings than Kestra Medical Technologies. NeuroPace is trading at a lower price-to-earnings ratio than Kestra Medical Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$99.99M	4.95	-$21.47M	-$0.57	N/A
Kestra Medical Technologies	$95.13M	15.79	-$131.61M	-$2.42	N/A

78.8% of NeuroPace shares are held by institutional investors. 19.2% of NeuroPace shares are held by company insiders. Comparatively, 5.3% of Kestra Medical Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

NeuroPace has a net margin of -19.34% compared to Kestra Medical Technologies' net margin of -138.35%. Kestra Medical Technologies' return on equity of -57.38% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroPace	-19.34%	-105.64%	-16.51%
Kestra Medical Technologies	-138.35%	-57.38%	-41.10%

Summary

NeuroPace beats Kestra Medical Technologies on 13 of the 17 factors compared between the two stocks.

How does NeuroPace compare to CONMED?

CONMED (NYSE:CNMD) and NeuroPace (NASDAQ:NPCE) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

CONMED has a net margin of 4.12% compared to NeuroPace's net margin of -19.34%. CONMED's return on equity of 14.31% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CONMED	4.12%	14.31%	6.33%
NeuroPace	-19.34%	-105.64%	-16.51%

CONMED has higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CONMED	$1.37B	1.09	$47.06M	$1.85	26.98
NeuroPace	$99.99M	4.95	-$21.47M	-$0.57	N/A

CONMED has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, NeuroPace has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market.

CONMED presently has a consensus price target of $41.40, suggesting a potential downside of 17.07%. NeuroPace has a consensus price target of $19.29, suggesting a potential upside of 33.84%. Given NeuroPace's stronger consensus rating and higher possible upside, analysts clearly believe NeuroPace is more favorable than CONMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CONMED	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

In the previous week, CONMED had 3 more articles in the media than NeuroPace. MarketBeat recorded 5 mentions for CONMED and 2 mentions for NeuroPace. NeuroPace's average media sentiment score of 1.17 beat CONMED's score of 0.95 indicating that NeuroPace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CONMED	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
NeuroPace	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.8% of NeuroPace shares are held by institutional investors. 0.3% of CONMED shares are held by insiders. Comparatively, 19.2% of NeuroPace shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

NeuroPace beats CONMED on 9 of the 17 factors compared between the two stocks.

How does NeuroPace compare to Omnicell?

Omnicell (NASDAQ:OMCL) and NeuroPace (NASDAQ:NPCE) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

Omnicell has higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.18B	1.27	$2.05M	$0.84	39.38
NeuroPace	$99.99M	4.95	-$21.47M	-$0.57	N/A

Omnicell has a net margin of 3.13% compared to NeuroPace's net margin of -19.34%. Omnicell's return on equity of 5.66% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	3.13%	5.66%	3.57%
NeuroPace	-19.34%	-105.64%	-16.51%

Omnicell has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market. Comparatively, NeuroPace has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market.

Omnicell currently has a consensus price target of $57.86, indicating a potential upside of 74.90%. NeuroPace has a consensus price target of $19.29, indicating a potential upside of 33.84%. Given Omnicell's higher possible upside, equities analysts clearly believe Omnicell is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

97.7% of Omnicell shares are owned by institutional investors. Comparatively, 78.8% of NeuroPace shares are owned by institutional investors. 2.9% of Omnicell shares are owned by company insiders. Comparatively, 19.2% of NeuroPace shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Omnicell had 5 more articles in the media than NeuroPace. MarketBeat recorded 7 mentions for Omnicell and 2 mentions for NeuroPace. Omnicell's average media sentiment score of 1.45 beat NeuroPace's score of 1.17 indicating that Omnicell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omnicell	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NeuroPace	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Omnicell beats NeuroPace on 12 of the 17 factors compared between the two stocks.

Get NeuroPace News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NPCE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NPCE vs. The Competition

Export

Metric	NeuroPace	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$494.61M	$5.88B	$7.21B	$12.90B
Dividend Yield	N/A	1.75%	2.54%	11.28%
P/E Ratio	-25.28	25.92	273.16	25.42
Price / Sales	4.95	68.66	630.81	94.42
Price / Cash	N/A	33.69	28.74	36.03
Price / Book	25.28	6.18	11.08	6.36
Net Income	-$21.47M	$149.94M	$3.48B	$349.79M
7 Day Performance	2.71%	-0.24%	0.13%	-0.80%
1 Month Performance	4.80%	6.18%	7.08%	4.13%
1 Year Performance	57.49%	6.30%	24.67%	15.17%

NeuroPace Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NPCE NeuroPace	3.496 of 5 stars	$14.41 +2.0%	$19.29 +33.8%	+57.5%	$494.61M	$99.99M	N/A	170
LMAT LeMaitre Vascular	4.8475 of 5 stars	$79.15 -1.0%	$110.60 +39.7%	-15.6%	$1.81B	$262.43M	27.78	490	Positive News
INSP Inspire Medical Systems	3.4067 of 5 stars	$61.13 -0.6%	$66.19 +8.3%	-34.5%	$1.77B	$911.98M	13.23	1,333	Positive News
KMTS Kestra Medical Technologies	1.7943 of 5 stars	$26.65 -1.0%	$28.14 +5.6%	+58.9%	$1.56B	$95.13M	N/A	300
CNMD CONMED	1.5869 of 5 stars	$50.94 -1.1%	$41.40 -18.7%	-8.1%	$1.53B	$1.37B	27.54	3,900

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NPCE) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeuroPace (NPCE) Competitors

NPCE vs. LMAT, INSP, KMTS, CNMD, and OMCL

How does NeuroPace compare to LeMaitre Vascular?

Summary

How does NeuroPace compare to Inspire Medical Systems?

Summary

How does NeuroPace compare to Kestra Medical Technologies?

Summary

How does NeuroPace compare to CONMED?

Summary

How does NeuroPace compare to Omnicell?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NPCE vs. The Competition

NeuroPace Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NeuroPace (NPCE) Competitors

NPCE vs. LMAT, INSP, KMTS, CNMD, and OMCL

How does NeuroPace compare to LeMaitre Vascular?

Do institutionals and insiders have more ownership in LMAT or NPCE?

Do analysts rate LMAT or NPCE?

Is LMAT or NPCE more profitable?

Which has more risk and volatility, LMAT or NPCE?

Does the media refer more to LMAT or NPCE?

Which has better valuation and earnings, LMAT or NPCE?

Summary

How does NeuroPace compare to Inspire Medical Systems?

Do institutionals & insiders have more ownership in NPCE or INSP?

Which has more risk and volatility, NPCE or INSP?

Is NPCE or INSP more profitable?

Does the media favor NPCE or INSP?

Do analysts prefer NPCE or INSP?

Which has better earnings and valuation, NPCE or INSP?

Summary

How does NeuroPace compare to Kestra Medical Technologies?

Do analysts prefer NPCE or KMTS?

Which has more volatility and risk, NPCE or KMTS?

Does the media favor NPCE or KMTS?

Which has higher valuation and earnings, NPCE or KMTS?

Do insiders & institutionals have more ownership in NPCE or KMTS?

Is NPCE or KMTS more profitable?

Summary

How does NeuroPace compare to CONMED?

Is CNMD or NPCE more profitable?

Which has stronger earnings & valuation, CNMD or NPCE?

Which has more volatility & risk, CNMD or NPCE?

Do analysts prefer CNMD or NPCE?

Does the media favor CNMD or NPCE?

Do insiders and institutionals have more ownership in CNMD or NPCE?

Summary

How does NeuroPace compare to Omnicell?

Which has better earnings & valuation, OMCL or NPCE?

Is OMCL or NPCE more profitable?

Which has more volatility & risk, OMCL or NPCE?

Do analysts prefer OMCL or NPCE?

Do insiders & institutionals have more ownership in OMCL or NPCE?

Does the media refer more to OMCL or NPCE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NPCE vs. The Competition

NeuroPace Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools